WASHINGTON, D.C. — The professional lives of Elizabeth Holmes and her husband, Billy Evans, remain deeply intertwined in the post-Theranos era. While Holmes focuses on rehabilitation, Evans has emerged as a central figure in Nathan Fielder’s upcoming documentary, raising questions about a potential second blood-testing venture.

The documentary, which premieres later this year, features Evans—a former chief information security officer at Intel—as a key voice. Fielder’s project examines the culture of radical honesty and the blurred lines between technology and deception. Evans is not portrayed merely as a spouse but as an active architect of the post-scandal brand strategy for the former Theranos CEO.

Speculation regarding a new entity, often dubbed "Theranos 2.0," has circulated among tech observers since late last year. Reports suggest Evans is consulting on a new diagnostic platform that leverages artificial intelligence. However, no official press release or SEC filing has confirmed the existence of a new public company under his direct leadership.

Key Takeaways

• Billy Evans is a primary subject in Nathan Fielder’s documentary, offering insights into the psychological aftermath of the Theranos fraud case.
• Investors are monitoring Evans’ activities, but there is zero verified public evidence of a new, operational blood-testing company under his direct control.
• The case highlights the difficulty regulators face in distinguishing between legitimate technological pivots and attempts to salvage fraudulent business models.

Legal experts note that Evans’ background in cybersecurity makes him a logical candidate for advising on data integrity in medical devices. "The market is skeptical of any new venture associated with this name," said David Marcus, a financial analyst at Meridian Capital. "Without a clear regulatory pathway, any new entrant faces an uphill battle for credibility."

Holmes herself remains under federal supervision for five years following her guilty plea in 2022. Her team has stated that she is "focused on the future" but has declined to comment on specific business plans. Evans has not responded to requests for comment regarding the documentary’s specific claims about new ventures.

For global investors, the situation underscores the risks associated with founder-led companies that collapse due to ethical breaches. The reputational shadow of the 2018 Theranos scandal, which involved the defrauding of investors of over $100 million, still looms large over any subsequent entrepreneurial efforts by its principals.

As the documentary releases, attention will shift from the legal proceedings to the narrative of redemption. Whether Evans is building a second company or simply helping his wife navigate life sentence conditions remains a distinction without a difference for cautious venture capital firms. The industry awaits concrete evidence before allocating capital to any proposed successor ventures.